Intro to Multifocal Motor Neuropathy (MMN)

Yes. MMN is typically slowly progressive without remission, meaning symptoms of muscle weakness tend to slowly increase over time if untreated, though treatment can improve function and slow progression.

The main FDA‑approved treatment for MMN is intravenous immunoglobulin (IVIg), which can improve motor function and slow disease progression; other treatments such as corticosteroids or plasma exchange are not effective and can worsen symptoms, and other therapies are under study but not widely proven.

Most patients who respond to IVIg will require ongoing repeated treatments (often every few weeks) to maintain improvement, and treatment is usually long‑term rather than a one‑time course.

Even with treatment, nerve damage can persist, and while IVIg can improve function by reducing immune attack and conduction block, muscles may remain weak if axonal loss has already occurred. Regular monitoring and adjustments in therapy can help.

Currently, there is no cure for MMN, but treatments like IVIg can improve symptoms and slow progression; research is ongoing to find better therapies.

Long‑term management includes regular treatment with IVIg, close monitoring by a neurologist, and supportive measures like physical therapy and adaptive techniques to help conserve energy and optimize muscle function; individualized care plans can help with fatigue and functional limitations.

You can connect with others and learn more through the GBS|CIDP Foundation International’s support community, including online forums, social media groups, local chapters, educational resources, community events, and Centers of Excellence that link patients with specialists and peer support.

MMN (Multifocal Motor Neuropathy) is a rare condition in which focal areas of multiple motor nerves are attacked by one’s own immune system. Typically, MMN is slowly progressive, resulting in asymmetrical weakness of a patient’s limbs. Patients frequently develop weakness in their hand(s), resulting in dropping of objects or sometimes inability to turn a key in a lock. The weakness associated with MMN can be recognized as fitting a specific nerve territory. There is essentially no numbness, tingling, or pain. Patients with MMN can have other symptoms, including twitching, or small random dimpling of the muscle under the skin which neurologists call fasciculations.

MMN is associated with increased levels of specific antibodies to GM1, a ganglioside or sugar-containing lipid found in peripheral nerve. Antibodies normally protect individuals from viruses and bacteria, but may under certain circumstances bind to and facilitate an immune attack on the peripheral nerve. These antibodies have been detected with newer assays in almost all of MMN patients. Even if these antibodies do not cause the nerve damage, they may be an important marker for disease and facilitate diagnosis.

The diagnosis of MMN is a clinical one that depends on demonstrating that the patient:

• has a purely motor disorder affecting individual nerves
• there are no UMN (upper motor neuron) signs such as brisk reflexes at the knees or ankles or spasticity in the limbs
• there is no difficulty speaking or swallowing
• there are no sensory deficits
• there is evidence of focal areas of nerve in which electrical impulses are slowed or blocked (conduction block) which can be detected on electrophysiology tests

These criteria are designed to differentiate MMN from ALS, (Lou Gehrig’s disease), Lewis-Sumner Syndrome (a multifocal inflammatory nerve disease with motor and sensory symptoms), and vasculitis or inflammation of small blood vessels in the peripheral nerve.

A neurologist is usually needed to determine the diagnosis, which is based on the history and physical examination. Tests include:

Laboratory testing for IgM GM1 antibodies is also frequently done.

an electrodiagnostic study, which includes nerve conduction studies (NCS) and needle electromyography (EMG).

It is now established that intravenous immunoglobin (IVIg), a preparation of antibodies obtained from healthy volunteers, can be readily given through an arm vein and provides benefit to patients with MMN. It is the only treatment for this disorder that is approved by the Federal Drug Administration (FDA) and regulatory agencies in Europe and Canada. IVIg can lead to improved motor function in most patients with MMN, with the response varying from minimal to very large. Early treatment shortly after symptom onset is always more effective. The treatment usually does not completely reverse all of the symptoms, and those patients who do respond will require repeated treatments to maintain their improvement. Patients usually require retreatment every 2-5 weeks and over time may need increased doses of IVIg.

IVIg is not a cure for MMN but currently no other therapy has proven to be widely effective. In a limited number of patients a cancer chemotherapy drug, cyclophosphamide, is temporarily effective. However, its use is limited by the toxic side-effects and risks that accrue with chronic use. Other immunosuppressive treatments such as corticosteroids and plasma exchange are ineffective and can actually make the disease worse.

Many investigators around the world are working towards a better understanding of MMN.